CD38 and Miyoshi myopathy: Isatuximab is a chimeric IgG1−κ anti-CD38 mAb which selectively targets a unique epitope on human CD38 receptor and induces anti-MM activity by direct apoptosis, CDC, ADCC, and ADCP (106).